

1. A method for increasing the sensitivity of a luminescent assay comprising carrying out the assay in the presence of an organic compound that reduces luminescence that is not dependent on the presence of an analyte by at least about 10 fold, and that reduces luminescence that is dependent on the presence of an analyte by less than about 7 fold.

2. A method for increasing the sensitivity of a luminescent assay comprising carrying out the assay in the presence of an organic compound that reduces luminescence generated by luminogenic molecules not bound to an enzyme by at least about 10 fold, and that reduces the luminescence generated by luminogenic molecules bound to an enzyme by less than about 7 fold.

$$\text{Subt } a^3$$

3. ~~A method for increasing the sensitivity of a luminescent assay comprising carrying out the assay in the presence of an organic compound that reduces autoluminescence by at least about 10 fold, and that reduces luminescence that is dependent on the presence of an analyte by less than about 7 fold.~~

4. The method of any one of claims 1-3 wherein the luminescent assay employs a luciferase, aequorin, or obelin enzyme.

5. The method of any one of claims 1-3 wherein the luminescent assay employs firefly luciferase.

6. The method of any one of claims 1-3 wherein the luminescent assay employs *Renilla* luciferase.

7. The method of any one of claims 1-3 wherein the luminescent assay employs *Cypridina* luciferase

8. The method of any one of claims 1-3 wherein the organic compound is present in a concentration of at least 0.1 μ M.

9. The method of any one of claims 1-3 wherein the organic compound is present in a concentration of at least 0.1 mM.

10. The method of any one of claims 1-3 wherein the organic compound is present in a concentration of from about 0.1 μ M to about 500 mM.

11. The method of any one of claims 1-3 wherein the organic compound is present in a concentration of from about 100 μ M to about 100 mM.

12. The method of any one of claims 1-3 wherein the organic compound is present in a concentration of from about 10 mM to about 100 mM.

13. The method of any one of claims 1-3 wherein the assay is performed in the presence of whole cells.

14. The method of any one of claims 1-3 wherein the assay is carried out in a solvent comprising at least about 10% water by weight.

15. ~~The method of any one of claims 1-3 wherein the assay is carried out in a solvent comprising at least about 25% water by weight.~~

16. The method of claim 1 wherein the luminescence that is dependent on the presence of an analyte is reduced by less than about 5 fold.

17. The method of claim 2 wherein the luminescence generated by luminogenic molecules bound to an enzyme is reduced by less than about 5 fold.

18. The method of claim 3 wherein the luminescence that is dependent on the presence of an analyte is reduced by less than about 5 fold.

19. The method of claim 1 wherein the luminescence that is dependent on the presence of an analyte is reduced by less than about 2 fold, remains the same, or is increased.

20. The method of claim 2 wherein the luminescence generated by luminogenic molecules bound to an enzyme is reduced by less than about 2 fold, remains the same, or is increased.

21. The method of claim 3 wherein the luminescence that is dependent on the presence of an analyte is reduced by less than about 2 fold, remains the same, or is increased.

22. An assay kit comprising packaging material containing 1) a luminogenic substrate of a luminescent enzyme, or a luminogenic enzyme; and 2) an organic compound for reducing luminescence that is not dependent on the presence of an analyte by at least about 10 fold, and for reducing luminescence that is dependent on the presence of an analyte by less than about 7 fold.

23. An assay kit comprising packaging material containing 1) a luminogenic substrate of a luminescent enzyme, or a luminogenic enzyme; and 2) an organic compound for reducing luminescence generated by luminogenic molecules not bound to an enzyme by at least about 10 fold, and for reducing luminescence generated by luminogenic molecules bound to an enzyme by less than about 7 fold.

24. An assay kit comprising packaging material containing 1) a luminogenic substrate of a luminescent enzyme, or a luminogenic enzyme; and 2) an organic compound for reducing autoluminescence by at least about 10 fold, and for reducing luminescence that is dependent on the presence of an analyte by less than about 7 fold.

25. The kit of any one of claims 22-24 wherein the enzyme substrate and the compound are each contained in a separate container

26. The kit of any one of claims 22-24 wherein the enzyme substrate and the compound are contained in a single container.

27. The kit of any one of claims 22-24 further comprising a buffer solution suitable for use in a luminescent assay.

28. The kit of claim 27 wherein the enzyme substrate and the buffer solution are contained in a single container.

29. The kit of claim 27 wherein the compound and the buffer solution are contained in a single container.

30. The kit of any one of claims 22-24 further comprising a substrate for a second luminescent enzyme.

31. The kit of any one of claims 22-24 further comprising a quenching agent for a luminescent enzyme reaction.

32. The kit of any one of claims 22-24 wherein the substrate is a substrate for firefly luciferase or *Renilla* luciferase.

- | Case | Age | Sex | Site | Pathologic Findings | Survival |
|------|-----|-----|--------|---------------------|------------|
| 1 | 65 | M | Rectum | Adenocarcinoma | 10 months |
| 2 | 68 | M | Rectum | Adenocarcinoma | 12 months |
| 3 | 70 | M | Rectum | Adenocarcinoma | 18 months |
| 4 | 72 | M | Rectum | Adenocarcinoma | 24 months |
| 5 | 75 | M | Rectum | Adenocarcinoma | 36 months |
| 6 | 78 | M | Rectum | Adenocarcinoma | 48 months |
| 7 | 80 | M | Rectum | Adenocarcinoma | 60 months |
| 8 | 82 | M | Rectum | Adenocarcinoma | 72 months |
| 9 | 85 | M | Rectum | Adenocarcinoma | 84 months |
| 10 | 88 | M | Rectum | Adenocarcinoma | 96 months |
| 11 | 90 | M | Rectum | Adenocarcinoma | 108 months |
| 12 | 92 | M | Rectum | Adenocarcinoma | 120 months |
| 13 | 95 | M | Rectum | Adenocarcinoma | 132 months |
| 14 | 98 | M | Rectum | Adenocarcinoma | 144 months |
| 15 | 100 | M | Rectum | Adenocarcinoma | 156 months |
| 16 | 102 | M | Rectum | Adenocarcinoma | 168 months |
| 17 | 105 | M | Rectum | Adenocarcinoma | 180 months |
| 18 | 108 | M | Rectum | Adenocarcinoma | 192 months |
| 19 | 110 | M | Rectum | Adenocarcinoma | 204 months |
| 20 | 112 | M | Rectum | Adenocarcinoma | 216 months |
| 21 | 115 | M | Rectum | Adenocarcinoma | 228 months |
| 22 | 118 | M | Rectum | Adenocarcinoma | 240 months |
| 23 | 120 | M | Rectum | Adenocarcinoma | 252 months |
| 24 | 122 | M | Rectum | Adenocarcinoma | 264 months |
| 25 | 125 | M | Rectum | Adenocarcinoma | 276 months |
| 26 | 128 | M | Rectum | Adenocarcinoma | 288 months |
| 27 | 130 | M | Rectum | Adenocarcinoma | 300 months |
| 28 | 132 | M | Rectum | Adenocarcinoma | 312 months |
| 29 | 135 | M | Rectum | Adenocarcinoma | 324 months |
| 30 | 138 | M | Rectum | Adenocarcinoma | 336 months |
| 31 | 140 | M | Rectum | Adenocarcinoma | 348 months |
| 32 | 142 | M | Rectum | Adenocarcinoma | 360 months |
| 33 | 145 | M | Rectum | Adenocarcinoma | 372 months |
| 34 | 148 | M | Rectum | Adenocarcinoma | 384 months |
| 35 | 150 | M | Rectum | Adenocarcinoma | 396 months |
| 36 | 152 | M | Rectum | Adenocarcinoma | 408 months |
| 37 | 155 | M | Rectum | Adenocarcinoma | 420 months |
| 38 | 158 | M | Rectum | Adenocarcinoma | 432 months |
| 39 | 160 | M | Rectum | Adenocarcinoma | 444 months |
| 40 | 162 | M | Rectum | Adenocarcinoma | 456 months |
| 41 | 165 | M | Rectum | Adenocarcinoma | 468 months |
| 42 | 168 | M | Rectum | Adenocarcinoma | 480 months |
| 43 | 170 | M | Rectum | Adenocarcinoma | 492 months |
| 44 | 172 | M | Rectum | Adenocarcinoma | 504 months |
| 45 | 175 | M | Rectum | Adenocarcinoma | 516 months |
| 46 | 178 | M | Rectum | Adenocarcinoma | 528 months |
| 47 | 180 | M | Rectum | Adenocarcinoma | 540 months |
| 48 | 182 | M | Rectum | Adenocarcinoma | 552 months |
| 49 | 185 | M | Rectum | Adenocarcinoma | 564 months |
| 50 | 188 | M | Rectum | Adenocarcinoma | 576 months |
| 51 | 190 | M | Rectum | Adenocarcinoma | 588 months |
| 52 | 192 | M | Rectum | Adenocarcinoma | 600 months |
| 53 | 195 | M | Rectum | Adenocarcinoma | 612 months |
| 54 | 198 | M | Rectum | Adenocarcinoma | 624 months |
| 55 | 200 | M | Rectum | Adenocarcinoma | 636 months |
| 56 | 202 | M | Rectum | Adenocarcinoma | 648 months |
| 57 | 205 | M | Rectum | Adenocarcinoma | 660 months |
| 58 | 208 | M | Rectum | Adenocarcinoma | 672 months |
| 59 | 210 | M | Rectum | Adenocarcinoma | 684 months |
| 60 | 212 | M | Rectum | Adenocarcinoma | 696 months |
| 61 | 215 | M | Rectum | Adenocarcinoma | 708 months |
| 62 | 218 | M | Rectum | Adenocarcinoma | 720 months |
| 63 | 220 | M | Rectum | Adenocarcinoma | 732 months |
| 64 | 222 | M | Rectum | Adenocarcinoma | 744 months |
| 65 | 225 | M | Rectum | Adenocarcinoma | 756 months |
| 66 | 228 | M | Rectum | Adenocarcinoma | 768 months |
| 67 | 230 | M | Rectum | Adenocarcinoma | 780 months |
| 68 | 232 | M | Rectum | Adenocarc | |

Date of Deposit: June 9, 2000

Date of Deposit: June 1, 2023
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 John A. Wise

Printed Name _____

Signature